Oral zidovudine continuous-infusion fluorouracil oral leucovorin calcium phase phase clinical pharmacologic biochemical evaluation oral zidovudine AZT days fixed dose continuous-infusion fluorouracil day days oral leucovorin calcium Eighteen patients doses AZT day Nausea vomiting dose limiting dose day Rash mucositis dose dose-related increase peak plasma levels AZT alpha half-life AZT plasma min high doses doses day trough levels absorption gut responses significant increase DNA single-strand breaks peripheral blood cells threshold dose day biological effect AZT regimen Further trials intravenous formulation capable plasma levels dose-limiting toxicity 